Edition:
United Kingdom

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

17.51USD
18 Jul 2018
Change (% chg)

$0.14 (+0.81%)
Prev Close
$17.37
Open
$17.39
Day's High
$17.52
Day's Low
$17.09
Volume
97,009
Avg. Vol
284,888
52-wk High
$21.47
52-wk Low
$11.43

Latest Key Developments (Source: Significant Developments)

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Halozyme reports Q3 EPS of $0.02
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Halozyme Therapeutics Inc :Halozyme reports third quarter 2017 results.Q3 earnings per share $0.02.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Q3 revenue $63.7 million versus i/b/e/s view $59 million.Sees FY 2017 ‍net revenue of $265 million to $280 million​.Qtrly ‍ cash, cash equivalents & marketable securities were $316.9 million at Sept. 30, 2017, versus $297.5 million at June 30, 2017​.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article

Halozyme reports second quarter 2016 financial results
Tuesday, 9 Aug 2016 

Halozyme Therapeutics Inc : Halozyme reports second quarter 2016 financial results . Q2 revenue $33.3 million versus I/B/E/S view $29.9 million . Sees FY 2016 revenue $140 million to $150 million . Q2 loss per share $0.21 . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Sees 2016 operating expenses to continue to be in range of $245 million to $260 million .FY2016 revenue view $138.7 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Abzena Gets Notice From Halozyme Of Termination Of Agreement

* GOT NOTICE FROM HALOZYME THERAPEUTICS OF TERMINATION OF COLLABORATION, LICENCE AGREEMENT RELATING TO HALOZYME'S USE OF CO'S THIOBRIDGE LINKER TECH Source text for Eikon: Further company coverage: